Michael J Kozal MD

Professor of Medicine (AIDS); Chief Section of Infectious Diseases VA CT Healthcare System; Director Yale HIV Clinical Trials; Acting Chief, Medical Service VACHS & Vice Chair, VA Medical Service for the Yale Dept. of Internal Medicine

Research Interests

Genetic determinants of HIV and Hepatitis C drug resistance; New technologies to detect low abundance drug resistant viral variants

Research Summary

Dr. Kozal's major research interests are the genetic determinants of HIV and Hepatitis C drug resistance. Dr. Kozal’s lab uses new deep sequencing technologies to detect minority resistant viral variants in patients and study the impact of these resistant variants on clinical outcomes. Dr. Kozal is the Director of HIV Clinical Trials at Yale and the VA and he is the principal investigator on multiple HIV and Hepatitis C clinical trials.

Selected Publications

  • Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St. John E, Moreno E and Kozal M. Virologic Failures on Initial boosted-PI Regimen Infrequently Possess Low-level Variants with Major PI Resistance Mutations by Ultra-deep Sequencing. PLoS One 2012;7(2):e30118. PMID: 22355307
  • Li JZ, Paredes R, Ribaudo H, Svarovskaia ES, Kozal MJ, et al. Relationship between Minority NNRTI Resistance Mutations, Adherence, and the Risk of Virologic Failure. AIDS. 2012 Jan 14;26(2):185-92. PMID: 22179227
  • Li JZ, Paredes R, Ribaudo H, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Minority HIV-1 Drug Resistance Mutations and the Risk of NNRTI-based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis. JAMA, 2011;305(13):1327-1335.
  • Kozal MJ, Chiarella J, St. John EP, et al. Prevalence of Low-level HIV-1 Variants with Reverse Transcriptase Mutation K65R Among Different HIV Subtypes and the Effects of Antiretroviral Drug Exposure on Variant Levels. Published early online July 13, 2011. Antiviral Therapy. 2011;16(6):925-9.
  • Thuy Le, Marcel Wolbers, Nguyen Huu Chi, Vo Minh Quang, Nguyen Tran Chinh Nguyen Phu Huong Lan, Pham Si Lam, Michael Kozal, Cecilia M. Shikuma, Jeremy N. Day, Jeremy Farrar. Epidemiology and Predictors of Outcome of Penicillium marneffei Infection at the Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam. Clin Infect Dis. 2011 Apr 1;52(7):945-52.
  • Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, Seekins D, Krystal M, Mancini M, McGrath D, Simen BB, Egholm M, and Kozal MJ. Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-deep Sequencing in Antiretroviral-naïve Subjects in the CASTLE Study. PLoS ONE 2010; Jun 3;5(6):e10952
  • Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, Landry ML, Dieckhaus K, Rosen MI, and Kozal MJ. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS ONE. 2009 Jun 29;4(6):e6079.
  • BB Simen, K Huppler Hullsiek, RM Novak, RD MacArthur, JD Baxter C Huang, C Lubeski, GS Turenchalk, MS Braverman, B Desany, JF Simons, JM Rothberg, M Egholm, and MJ Kozal. Low Abundance Drug Resistant Viral Variants in Chronically HIV-infected Antiretroviral-Naïve Patients Significantly Impact Treatment. Journal of Infectious Diseases 2009;199(5):693-701.
  • Kozal MJ. Drug Resistant Human Immunodeficiency Virus. Supplement: Environmental changes, microbial systems and infections Clin Microbiol Infect. 2009 Jan15 Suppl 1:69-73.
  • Kozal MJ, K Huppler Hullsiek, RD MacArthur, G Peng, Y. Xiang, JD Baxter M Van den Berg-Wolf, J Uy, EE Telzak and RM Novak. The Incidence of HIV Drug Resistance and Its Impact on Progression of HIV Disease Among Antiretroviral Naïve Participants Started on Three Different Antiretroviral Therapy Strategies. HIV Clinical Trials 2007;6(6):357-370.


Edit Profile